{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.508","meta":{"versionId":"12","lastUpdated":"2023-04-03T13:49:33.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"CancerLinQ Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-04-03"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.508","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1116.508"}],"version":"20191204","name":"FlowCytometryStudiesPerformed","title":"Flow Cytometry Studies Performed","status":"active","experimental":false,"date":"2019-12-04T01:00:20-05:00","publisher":"CancerLinQ Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","concept":[{"code":"1012415","display":"Flow cytometry, interpretation"},{"code":"3170F","display":"Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)"},{"code":"88184","display":"Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker"},{"code":"88185","display":"Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)"},{"code":"88187","display":"Flow cytometry, interpretation; 2 to 8 markers"},{"code":"88189","display":"Flow cytometry, interpretation; 16 or more markers"}]}]},"expansion":{"identifier":"urn:uuid:9a1bdf02-9bcd-45d1-a33f-e9a287284c9f","timestamp":"2023-12-10T21:41:40-05:00","total":6,"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"1012415","display":"Flow cytometry, interpretation"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"3170F","display":"Baseline flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"88184","display":"Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"88185","display":"Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"88187","display":"Flow cytometry, interpretation; 2 to 8 markers"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"88189","display":"Flow cytometry, interpretation; 16 or more markers"}]}}